{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:54:25Z","timestamp":1779911665002,"version":"3.53.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Institute for Convergence of Biomedical Science and Technology Pusan National University Yangsan Hospital","award":["30-2016-017"],"award-info":[{"award-number":["30-2016-017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To investigate the cytotoxicities of the topical ocular dual-action anti-allergic agents (alcaftadine 0.25%, bepotastine besilate 1.5%, and olopatadine HCL 0.1%) on human corneal epithelial cells (HCECs) and their anti-allergic effects on cultured conjunctival epithelial cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Methylthiazolyltetrazolium(MTT)-based calorimetric assay was used to assess cytotoxicities using HCECs at concentrations of 10, 20 or 30% for exposure durations of 30\u2009min, 1\u2009h, 2\u2009h, 12\u2009h or 24\u2009h. Cellular morphologies were evaluated by inverted phase-contrast and electron microscopy. Wound widths were measured 2\u2009h, 18\u2009h, or 24\u2009h after confluent HCECs monolayers were scratched. Realtime PCR was used to quantify anti-allergic effects on cultured human conjunctival cells, in which allergic reactions were induced by treating them with<jats:italic>Aspergillus<\/jats:italic>antigen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Cell viabilities decreased in time- and concentration-dependent manners. Cells were detached from dishes and showed microvilli loss, cytoplasmic vacuoles, and nuclear condensation when exposed to antiallergic agents; alcaftadine was found to be least cytotoxic. Alcaftadine treated HCECs monolayers showed the best wound healing followed by bepotastine and olopatadine (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). All agents significantly reduced the gene expressions of allergic cytokines (IL-5, IL-25, eotaxin, thymus and activation-regulated chemokine, and thymic stromal lymphopoietin) and alcaftadine had the greatest effect (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001 in all cases).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Alcaftadine seems to have less side effects and better therapeutic effects than the other two anti-allergic agents tested. It may be more beneficial to use less toxic agents for patients with ocular surface risk factors or presumed symptoms of toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12886-019-1228-5","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T15:12:32Z","timestamp":1573225952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents"],"prefix":"10.1186","volume":"19","author":[{"given":"Sung Il","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choul Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"Fordjuor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Heon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4927-2854","authenticated-orcid":false,"given":"Ji Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"issue":"4","key":"1228_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1365-2222.2006.02463.x","volume":"36","author":"SF Bloomfield","year":"2006","unstructured":"Bloomfield SF, Stanwell-Smith R, Crevel RW, Pickup J. Too clean, or not too clean: the hygiene hypothesis and home hygiene. Clin Exp Allergy. 2006;36(4):402\u201325.","journal-title":"Clin Exp Allergy"},{"issue":"Suppl 79","key":"1228_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1398-9995.2005.00854.x","volume":"60","author":"TA Platts-Mills","year":"2005","unstructured":"Platts-Mills TA, Erwin E, Heymann P, Woodfolk J. Is the hygiene hypothesis still a viable explanation for the increased prevalence of asthma? Allergy. 2005;60(Suppl 79):25\u201331.","journal-title":"Allergy."},{"issue":"2","key":"1228_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5415\/apallergy.2017.7.2.57","volume":"7","author":"BY Thong","year":"2017","unstructured":"Thong BY. Allergic conjunctivitis in Asia. Asia Pac Allergy. 2017;7(2):57\u201364.","journal-title":"Asia Pac Allergy"},{"issue":"1","key":"1228_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1398-9995.2008.01884.x","volume":"64","author":"ISAAC Phase Three Study Group","year":"2009","unstructured":"ISAAC Phase Three Study Group. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the international study of asthma and allergies in childhood (ISAAC) phase three. Allergy. 2009;64(1):123\u201348.","journal-title":"Allergy."},{"issue":"5","key":"1228_CR5","first-page":"494","volume":"116","author":"K Fukagawa","year":"2012","unstructured":"Fukagawa K, Fujishima H, Fukushima A, Sumi T, Okamoto S, Shoji J, et al. A quality of life questionnaire for Japanese allergic conjunctival disease. Nippon Ganka Gakkai Zasshi. 2012;116(5):494\u2013502.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"5","key":"1228_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/00130832-200110000-00015","volume":"1","author":"A Solomon","year":"2001","unstructured":"Solomon A, Pe'er J, Levi-Schaffer F. Advances in ocular allergy: basic mechanisms, clinical patterns and new therapies. Curr Opin Allergy Clin Immunol. 2001;1(5):477\u201382.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"1228_CR7","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1517\/14656561003694643","volume":"11","author":"A Leonardi","year":"2010","unstructured":"Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opin Pharmacother. 2010;11(6):969\u201381.","journal-title":"Expert Opin Pharmacother"},{"key":"1228_CR8","first-page":"1495","volume":"8","author":"MT Bergmann","year":"2014","unstructured":"Bergmann MT, Williams JI, Gomes PJ. Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%. Clin Ophthalmol. 2014;8:1495\u2013505.","journal-title":"Clin Ophthalmol"},{"key":"1228_CR9","first-page":"87","volume":"5","author":"JV Greiner","year":"2011","unstructured":"Greiner JV, Edwards-Swanson K, Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol. 2011;5:87\u201393.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1228_CR10","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1167\/iovs.14-15982","volume":"56","author":"JE Lee","year":"2015","unstructured":"Lee JE, Sun Y, Gjorstrup P, Pearlman E. Inhibition of corneal inflammation by the Resolvin E1. Invest Ophthalmol Vis Sci. 2015;56(4):2728\u201336.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1228_CR11","first-page":"851","volume":"18","author":"C Clouzeau","year":"2012","unstructured":"Clouzeau C, Godefroy D, Riancho L, Rost\u00e8ne W, Baudouin C, Brignole-Baudouin F. Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro. Mol Vis. 2012;18:851\u201363.","journal-title":"Mol Vis"},{"key":"1228_CR12","first-page":"77","volume-title":"Physiology","author":"YS Park","year":"2000","unstructured":"Park YS. Physiology of body fluid. In: Kang DH, editor. Physiology. Seoul: Sin-Kwang; 2000. p. 77\u201398."},{"issue":"5","key":"1228_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/ICO.0000000000000368","volume":"34","author":"RM Dutescu","year":"2015","unstructured":"Dutescu RM, Panfil C, Schrage N. Osmolarity of prevalent eye drops, side effects, and therapeutic approaches. Cornea. 2015;34(5):560\u20136.","journal-title":"Cornea."},{"key":"1228_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2415-9-5","volume":"9","author":"S Khoh-Reiter","year":"2009","unstructured":"Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol. 2009;9:5.","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"1228_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1089\/jop.2008.0071","volume":"24","author":"JS Lee","year":"2008","unstructured":"Lee JS, Lee JE, Kim N, Oum BS. Comparison of the conjunctival toxicity of topical ocular antiallergic agents. J Ocul Pharmacol Ther. 2008;24(6):557\u201362.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"1228_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5650\/jos.60.139","volume":"60","author":"M Ayaki","year":"2011","unstructured":"Ayaki M, Iwasawa A, Yaguchi S, Koide R. In vitro assessment of the cytotoxicity of anti-allergic eye drops using 5 cultured corneal and conjunctival cell lines. J Oleo Sci. 2011;60(3):139\u201344.","journal-title":"J Oleo Sci"},{"key":"1228_CR17","first-page":"77","volume":"5","author":"SJ Ono","year":"2011","unstructured":"Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Des Devel Ther. 2011;5:77\u201384.","journal-title":"Drug Des Devel Ther"},{"key":"1228_CR18","first-page":"124","volume":"19","author":"U Ziegler","year":"2004","unstructured":"Ziegler U, Groscurth P. Morphological features of cell death. News Physiol Sci. 2004;19:124\u20138.","journal-title":"News Physiol Sci"},{"key":"1228_CR19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/0002-9394(60)91806-7","volume":"49","author":"DL Merrill","year":"1960","unstructured":"Merrill DL, Fleming TC, Girard LJ. The effects of physiologic balanced salt solutions and normal saline on intraocular and extraocular tissue. Am J Ophthalmol. 1960;49:895\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1228_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312\u201334.","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"1228_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1089\/jop.2014.0030","volume":"30","author":"A Guzman-Aranguez","year":"2014","unstructured":"Guzman-Aranguez A, Calvo P, Ropero I, Pintor J. In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells. J Ocul Pharmacol Ther. 2014;30(9):790\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"1228_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4265\/bio.15.143","volume":"15","author":"M Ayaki","year":"2010","unstructured":"Ayaki M, Iwasawa A, Yaguchi S, Koide R. Preserved and unpreserved 12 anti-allergic ophthalmic solutions and ocular surface toxicity: in vitro assessment in four cultured corneal and conjunctival epithelial cell lines. Biocontrol Sci. 2010;15(4):143\u20138.","journal-title":"Biocontrol Sci"},{"key":"1228_CR23","first-page":"745","volume":"17","author":"A Pauly","year":"2011","unstructured":"Pauly A, Brasnu E, Riancho L, Brignole-Baudouin F, Baudouin C. Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Mol Vis. 2011;17:745\u201355.","journal-title":"Mol Vis"},{"issue":"4","key":"1228_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/02713680801971857","volume":"33","author":"E Brasnu","year":"2008","unstructured":"Brasnu E, Brignole-Baudouin F, Riancho L, Guenoun JM, Warnet JM, Baudouin C. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008;33(4):303\u201312.","journal-title":"Curr Eye Res"},{"key":"1228_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1076\/0271-3683(200002)2021-DFT085","volume":"20","author":"JM De Saint","year":"2000","unstructured":"De Saint JM, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20:85\u201394.","journal-title":"Curr Eye Res"},{"key":"1228_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3109\/02713683.2013.859275","volume":"39","author":"MM Feng","year":"2014","unstructured":"Feng MM, Baryla J, Liu H, Laurie GW, McKown RL, Ashki N, et al. Cytoprotective effect of lacritin on human corneal epithelial cells exposed to benzalkonium chloride in vitro. Curr Eye Res. 2014;39:604\u201310.","journal-title":"Curr Eye Res"},{"issue":"1","key":"1228_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/IJG.0000000000000279","volume":"25","author":"R Pinheiro","year":"2016","unstructured":"Pinheiro R, Panfil C, Schrage N, Dutescu RM. The impact of Glaucoma medications on corneal wound healing. J Glaucoma. 2016;25(1):122\u20137.","journal-title":"J Glaucoma"},{"issue":"2","key":"1228_CR28","first-page":"215","volume":"8","author":"JS Lee","year":"2015","unstructured":"Lee JS, Lee SU, Che CY, Lee JE. Comparison of cytotoxicity and wound healing effect of carboxymethylcellulose and hyaluronic acid on human corneal epithelial cells. Int J Ophthalmol. 2015;8(2):215\u201321.","journal-title":"Int J Ophthalmol"},{"key":"1228_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.preteyeres.2015.07.002","volume":"49","author":"AV Ljubimov","year":"2015","unstructured":"Ljubimov AV, Saghizadeh M. Progress in corneal wound healing. Prog Retin Eye Res. 2015;49:17\u201345.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"1228_CR30","doi-asserted-by":"crossref","first-page":"42726","DOI":"10.1155\/MI\/2006\/42726","volume":"2006","author":"K Kishimoto","year":"2006","unstructured":"Kishimoto K, Kaneko S, Ohmori K, Tamura T, Hasegawa K. Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediat Inflamm. 2006;2006(1):42726.","journal-title":"Mediat Inflamm"},{"issue":"2","key":"1228_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2174\/1872213X08666140704113452","volume":"8","author":"AH Wong","year":"2014","unstructured":"Wong AH, Barg SS, Leung AK. Seasonal and perennial allergic conjunctivitis. Recent Patents Inflamm Allergy Drug Discov. 2014;8(2):139\u201353.","journal-title":"Recent Patents Inflamm Allergy Drug Discov"},{"issue":"6","key":"1228_CR32","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1365-2222.2009.03241.x","volume":"39","author":"YH Wang","year":"2009","unstructured":"Wang YH, Liu YJ. Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. Clin Exp Allergy. 2009;39(6):798\u2013806.","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"1228_CR33","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.4049\/jimmunol.169.5.2712","volume":"169","author":"A Menzies-Gow","year":"2002","unstructured":"Menzies-Gow A, Ying S, Sabroe I, Stubbs VL, Soler D, Williams TJ, Kay AB. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol. 2002;169(5):2712\u20138.","journal-title":"J Immunol"},{"issue":"23","key":"1228_CR34","doi-asserted-by":"publisher","first-page":"15036","DOI":"10.1074\/jbc.272.23.15036","volume":"272","author":"T Imai","year":"1997","unstructured":"Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem. 1997;272(23):15036\u201342.","journal-title":"J Biol Chem"},{"key":"1228_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev.immunol.25.022106.141718","volume":"25","author":"YJ Liu","year":"2007","unstructured":"Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt Rde W, et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193\u2013219.","journal-title":"Annu Rev Immunol"},{"key":"1228_CR36","first-page":"9","volume":"5","author":"A Gallois-Bernos","year":"2012","unstructured":"Gallois-Bernos A, Thurmond R. Alcaftadine, a new antihistamine with combined antagonist activity at histamine H1, H2, and H4 receptors. J Recept Ligand Channel Res. 2012;5:9\u201320.","journal-title":"J Recept Ligand Channel Res"},{"issue":"2","key":"1228_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/jop.2010.0153","volume":"27","author":"H Bohets","year":"2011","unstructured":"Bohets H, McGowan C, Mannens G, Schroeder N, Edwards-Swanson K, Shapiro A. Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis. J Ocul Pharmacol Ther. 2011;27(2):187\u201395.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"1228_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1089\/jop.1996.12.401","volume":"12","author":"NA Sharif","year":"1996","unstructured":"Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther. 1996;12(4):401\u20137.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1228_CR39","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2147\/OPTH.S63790","volume":"9","author":"DI Chigbu","year":"2015","unstructured":"Chigbu DI, Coyne AM. Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis. Clin Ophthalmol. 2015;9:1215\u201325.","journal-title":"Clin Ophthalmol"},{"key":"1228_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/JAA.S38671","volume":"6","author":"S Ackerman","year":"2013","unstructured":"Ackerman S, D'Ambrosio F Jr, Greiner JV, Villanueva L, Ciolino JB, Hollander DA. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. J Asthma Allergy. 2013;6:43\u201352.","journal-title":"J Asthma Allergy"},{"issue":"10","key":"1228_CR41","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s12325-014-0155-3","volume":"31","author":"EB McLaurin","year":"2014","unstructured":"McLaurin EB, Marsico NP, Ackerman SL, Ciolino JB, Williams JM, Villanueva L, et al. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther. 2014;31(10):1059\u201371.","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"1228_CR42","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1097\/ICO.0000000000000997","volume":"35","author":"X Zheng","year":"2016","unstructured":"Zheng X, Yamaguchi M, Kamao T, Sakane Y, Goto T, Shiraishi A, et al. Visualization of tear clearance using anterior segment optical coherence tomography and Polymethylmethacrylate particles. Cornea. 2016;35(Suppl 1):S78\u201382.","journal-title":"Cornea."},{"issue":"6","key":"1228_CR43","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/bjo.82.6.666","volume":"82","author":"P Prabhasawat","year":"1998","unstructured":"Prabhasawat P, Tseng SC. Frequent association of delayed tear clearance in ocular irritation. Br J Ophthalmol. 1998;82(6):666\u201375.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1228_CR44","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0002-9394(00)00822-9","volume":"131","author":"MT Yen","year":"2001","unstructured":"Yen MT, Pflugfelder SC, Feuer WJ. The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects. Am J Ophthalmol. 2001;131(3):314\u201323.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1228_CR45","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ajo.2010.01.004","volume":"149","author":"Y Yuan","year":"2010","unstructured":"Yuan Y, Wang J, Chen Q, Tao A, Shen M, Shousha MA. Reduced tear meniscus dynamics in dry eye patients with aqueous tear deficiency. Am J Ophthalmol. 2010;149(6):932\u20138.","journal-title":"Am J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1228-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1228-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1228-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T15:11:38Z","timestamp":1722006698000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1228-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1228-5","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"6 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Choul Yong Park is an section editor and Ji Eun Lee is an associate editor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}